HTG Molecular Diagnostics, Inc.
HTGMQ · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $6,366 | $8,907 | $8,549 | $19,204 |
| % Growth | -28.5% | 4.2% | -55.5% | – |
| Cost of Goods Sold | $4,572 | $4,095 | $3,992 | $8,911 |
| Gross Profit | $1,794 | $4,812 | $4,557 | $10,293 |
| % Margin | 28.2% | 54% | 53.3% | 53.6% |
| R&D Expenses | $6,782 | $6,089 | $6,080 | $10,570 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $15,842 | $16,547 | $18,063 | $18,682 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $417 | $0 |
| Operating Expenses | $22,624 | $22,636 | $24,560 | $29,253 |
| Operating Income | -$20,830 | -$17,824 | -$19,586 | -$18,960 |
| % Margin | -327.2% | -200.1% | -229.1% | -98.7% |
| Other Income/Exp. Net | -$754 | $701 | -$1,270 | -$334 |
| Pre-Tax Income | -$21,584 | -$17,123 | -$20,856 | -$19,294 |
| Tax Expense | $11 | $22 | $14 | $3 |
| Net Income | -$21,594 | -$17,145 | -$20,870 | -$19,298 |
| % Margin | -339.2% | -192.5% | -244.1% | -100.5% |
| EPS | -24.28 | -29.66 | -54.12 | -91.17 |
| % Growth | 18.1% | 45.2% | 40.6% | – |
| EPS Diluted | -24.28 | -29.66 | -54.12 | -91.17 |
| Weighted Avg Shares Out | 889 | 578 | 386 | 212 |
| Weighted Avg Shares Out Dil | 889 | 578 | 386 | 212 |
| Supplemental Information | – | – | – | – |
| Interest Income | $94 | $30 | $255 | $623 |
| Interest Expense | $857 | $1,065 | $1,025 | $958 |
| Depreciation & Amortization | $587 | $721 | $1,347 | $1,259 |
| EBITDA | -$20,140 | -$15,357 | -$18,484 | -$17,078 |
| % Margin | -316.4% | -172.4% | -216.2% | -88.9% |